Some of Wednesday's midday movers:» Read More
ZURICH, March 7- Novartis drug Jakavi achieved its main goal in a late-stage trial for patients suffering from a rare blood cancer, putting it on track to become a potential blockbuster treatment with sales of $1 billion- plus.
Feb 25- Anika Therapeutics Inc said the U.S. Food and Drug Administration approved its drug to treat pain and improve joint mobility in patients with osteoarthritis of the knee, more than four years after it first filed for approval.
Feb 25- Vivus Inc's silence on its strategy to boost sales of obesity drug Qsymia has increased doubts about whether the pill will reach its full commercial potential. Analysts said on Tuesday that Vivus, with its limited sales force, needed a partner to ensure the drug's success.
NEW YORK/ LONDON, Feb 19- A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck& Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter.
Feb 18- After a nearly three-year campaign at Forest Laboratories Inc that spanned two proxy battles and the ousting of a chief executive, billionaire activist investor Carl Icahn has once again ended up on top.
*L'Oreal buys 8 pct stake from Nestle for 6.5 bln euros. *Nestle stake cut to 23 pct, but says in for long haul. *Deal will boost L'Oreal EPS, Nestle to do share buyback.
*L'Oreal does not need to sell Sanofi stake for Nestle deal. *Hopes recede for debt-funded buyback of stake by Sanofi.
*Bloomberg said Nestle looking to cut L'Oreal stake. Bloomberg reported on Friday that Swiss food group Nestle was looking at ways to reduce its L'Oreal stake, which is currently worth more than 23 billion euros.
LONDON, Feb 10- European shares traded flat on Monday, as cosmetics maker L'Oreal gained on expectations it will buy back its shares owned by Nestle and helped to keep the market steady after its recent gains.
PARIS, Feb 6- French drugmaker Sanofi's forecast for a return to profit growth after three years of decline failed to impress investors on Thursday, sending its shares to a one-year low.
The CEO of Sanofi admitted the pharmaceutical giant underperformed in emerging markets last year, after reporting a decline in quarterly sales.
MUMBAI/ LONDON, Feb 6- Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.
PARIS, Feb 6- European shares rose in early trade on Thursday, bouncing back from a sharp two-week selloff, with telecom gear maker Alcatel-Lucent surging 7.4 percent after posting reassuring results. The market's rebound could be limited, however, ahead of a European Central Bank meeting later in the day.
Markets are in wait-and-see mode ahead of Friday's jobs report, but there are a few events Thursday that could sway the market's direction.
Feb 4- Ten big rival drug companies have formed a pact to cooperate on a government-backed effort to accelerate the discovery of new drugs, the Wall Street Journal reported.
Some of the names on the move ahead of the open.
Chris Viehbacher, CEO of Sanofi, says 2013 was a big year for biotech IPOs as companies were coming to market to access cash for the first time after many years.
Sanofi's Lemtrada multiple sclerosis treatment has failed to win approval from U.S. regulators, dealing a setback to a drug which was at the heart of the French drugmaker's $20 billion takeover of biotech firm Genzyme.
Next year is an election year. There is little chance of a big tax increase, or a government shutdown or debt crisis.
Some of Thursday's midday movers: